Diabetes medicine update. Old dogs, new tricks.
Nakamoto
Mark
M
D002839:Chromans / Q000009:adverse effects / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004338:Drug Combinations; D004348:Drug Labeling; D005913:Glipizide / Q000627:therapeutic use; D005905:Glyburide / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D017093:Liver Failure / Q000139:chemically induced; D008687:Metformin / Q000627:therapeutic use; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D004338:Drug Combinations; C417231:Glucovance; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; C471073:metaglip; C471074:rosiglitazone-metformin combination; D000077154:Rosiglitazone; D008687:Metformin; D000077288:Troglitazone; D005905:Glyburide; D000077205:Pioglitazone; D005913:Glipizide